secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001104659-23-108359
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed postpones Virtue SAB pivotal study to 2024 amid Terumo negotiations
--------------------------------------------------------------------------------

- Filed registration statement for resale of shares/warrants; not seeking additional capital.
- Negotiating with Terumo to restructure milestone payments and modify distribution agreement.
- Virtue ISR-US pivotal study initiation postponed to 2024 due to ongoing negotiations.
- If negotiations not satisfactory, clinical/commercial plans for Virtue SAB may be further affected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923108359/0001104659-23-108359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923108359/tm2328162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-108359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer